A Two-Week, Randomised, Double-Blind Study Assessing the Onset of Effect Questionnaire Administered Pre-Dose Versus Post-Dose in Adult Subjects (greater than or equal to 18 years) With Mild to Moderate Asthma, Receiving SYMBICORT pMDI [pressurised metered-dose inhaler] 80/4.5 microg x 2 Actuations Twice Daily or Budesonide HFA [hydrofluoroalkane] pMDI 80 microg x 2 Act. Twice Daily.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Budesonide (Primary) ; Budesonide/formoterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 01 Apr 2009 Actual patient number (134) added as reported by ClinicalTrials.gov record (NCT00449501).
- 11 Jan 2008 Status changed from in progress to completed.
- 12 Oct 2007 Status changed from recruiting to in progress.